[Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone].
OBJECTIVE
Androgen suppression in prostate cancer is responsible for many side effects. Many studies, mostly retrospective, have found an association between androgen deprivation and increased cardiovascular morbidity. If the cardiovascular impact was chosen, an etiological explanation would be the occurrence of metabolic disorders, particularly insulin resistance. The objective of our work was to conduct a review of the literature assessing the impact of androgen deprivation on the onset of insulin resistance, the metabolic syndrome and changes in key markers of insulin resistance.


METHODS
A systematic review of literature from the Pubmed database search was performed using the following keywords: androgen deprivation therapy, metabolic syndrome, insulin resistance, hyperglycemia, cardiovascular diseases, cardiovascular risk, abdominal obesity.


RESULTS
Twelve studies were included, bringing into focus a 55% prevalence of metabolic syndrome in patients treated for more than 12 months, an increase in fat mass and decreased lean body mass, an increase in abdominal subcutaneous fat and in visceral adiposity. The insulin was increased in four studies (25 to 60% three months dice). The increased insulin resistance was assessed by the Homeostasis Model Assessment (HOMA) was postponed three times (12% in two prospective cohort studies of type). The increase in triglycerides (20 to 40% at 12 months) and total cholesterol (7 to 11%) was observed in five studies, and increased LDL cholesterol and HDL in three studies (9 to 22%).


CONCLUSIONS
All studies of this analysis appeared to converge towards the development of insulin resistance and metabolic disorders, however, no prospective cohort study of good methodological quality were identified. It would be necessary to conduct a prospective multicenter study in order to have a causal quality.
Service d'urologie-andrologie, université Jean-Monnet, CHU de Saint-Étienne, 34, rue Francis-Baulier, 42023 Saint-Étienne cedex 2, France. jetterrier@yahoo.fr
J-E
JE
Terrier
N
N
Mottet
D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D015415:Biomarkers; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D019317:Evidence-Based Medicine; D005602:France / Q000453:epidemiology; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D056128:Obesity, Abdominal / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood
D000726:Androgen Antagonists; D015415:Biomarkers; D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007328:Insulin; D014280:Triglycerides; D002784:Cholesterol